Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01160380 · ClinicalTrials.gov registry record · Phase 3
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase 3 study, sponsored by Oncotherapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
NCT01160380 is a Phase 3 study that has completed, run by Oncotherapeutics. The registered enrollment target is 50 participants.
The verdict
NCT01160380, a Phase 3 study, has completed, sponsored by Oncotherapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of armodafinil for the treatment of cancer-related fatigue in adult patients with multiple myeloma. The study consists of a screening period, followed by a 56-day treatment phase, and a final assessment to occur 28 days after the end of the last treatment.
Interventions
- DRUG Placebo
- DRUG armodafinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-06 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01160380
The ClinicalTrials.gov registry entry for NCT01160380 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oncotherapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01160380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01160380 about?
NCT01160380 is a clinical study titled "A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma". The purpose of this study is to evaluate the efficacy of armodafinil for the treatment of cancer-related fatigue in adult patients with multiple myeloma. The study consists of a screening period, followed by a 56-day treatment phase, and a final assessment to occur 28 days after the end of the last ...
What is the current status of trial NCT01160380?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2010-06. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01160380?
The interventions under investigation include: Placebo (DRUG), armodafinil (DRUG).
Who is sponsoring clinical trial NCT01160380?
This trial is sponsored by Oncotherapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.